BioCentury on BioBusiness,
How Raptor is making its case for ultra-Orphan drug Procysbi's $250,000 price
Paying for Procysbi
Monday, May 20, 2013
Pharmaceutical Corp. will launch an ultra-Orphan drug this quarter that it has shown to be
non-inferior to a cheaper alternative. The company has yet to get any payers on
board, but believes it can win them over based on the drug's ability to improve
compliance and quality of life for patients with nephropathic cystinosis.
Raptor has set the U.S. list price of Procysbi (RP103) at
$250,000 annually. The immediate-release formulation of the drug, Cystagon
cysteamine, is marketed by Mylan Inc. for
about $10,000 per year.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]